IL2 and neoplasm: Furthermore, compared with the direct co-administration of wild-type or engineered IL-2 in vivo with T cell transfer, synthetic cytokine circuits such as tumor-specific synNotch receptors and synthetic zinc finger transcription regulators (synZiFTRs) on engineered T cells allowed the precise production of IL-2 in time and space to achieve less systemic toxicity [74, 80].